Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Wr-Pri LLC

Neither a doctor nor a teaching hospital

Research payments

$3,350,664

505 payments

Through program year 2025, Wr-Pri LLC is reported as receiving $3,350,664 in research payments, across 505 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $83,689 22
2024 Research $311,452 53
2023 Research $520,128 98
2022 Research $265,879 84
2021 Research $736,401 111
2020 Research $1,195,869 107
2019 Research $237,246 30

Breakdown

Who paid Research payments · program years 2019–2025
  1. Allergan Inc. $675,291 143 payments
  2. Biohaven Pharmaceuticals, Inc. $641,773 58 payments
  3. Sage Therapeutics, Inc. $562,112 45 payments
  4. AbbVie, Inc. $481,496 134 payments
  5. Otsuka Pharmaceutical Development & Commercialization, Inc. $457,690 11 payments
  6. ITI, Inc. $270,369 67 payments
  7. Novavax Inc $154,921 13 payments
  8. Biohaven Pharmaceutical Holding Company Ltd. $76,931 26 payments
  9. AMAG Pharmaceuticals, Inc. $12,941 2 payments
  10. Janssen Research & Development, LLC $8,800 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine $345,057 102 payments
  2. A Phase 2/3 Open-label Long-Term Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine $331,130 30 payments
  3. A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment With Sage-217 in Adult Subjects With Major Depressive Disorder $315,076 30 payments
  4. An Open-Label, 52-Week, Multicenter Trial Evaluating the Long-Term Safety and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder $293,454 4 payments
  5. BHV3500-301: Phase 3: Double-Blind Randomized Placebo Controlled Safety and Efficacy Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine $214,612 43 payments
  6. A Phase 3, Multicenter, Randomized, Open-Label Study to Evaluate the Longterm Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Patients With Episodic Migraine $198,310 25 payments
  7. A Phase 3, Open-Label, 1-Year Study of the Safety, Tolerability, and Need for Re-Treatment with SAGE-217 in Adult Subjects with Major Depressive Disorder $171,474 5 payments
  8. A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Matrix-M1 Adjuvant in Adult Participants older than or equal to 18 Years With a Pediatric Expansion in Adolescents (12 to < 18 Years) $152,299 12 payments
  9. An Open-Label Multicenter Trial to Assess the Safety and Tolerability of Lumateperone As Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder $136,904 35 payments
  10. A Phase 2/3 Open-label, Long-Term, Safety Trial of BHV3500 (zavegepant) Intranasal (IN) for the Acute Treatment of Migraine $126,959 6 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record